Danish Bavarian Nordic receives contract valued up to USD 228 Million from the U.S. Government.
On April 16, Bavarian Nordic A/S announced that BARDA (Biomedical Advanced Research and Development Authority), a division of the U.S. Department of Health & Human Services (HHS), has awarded the company a contract valued at up to USD 228 million for the continued supply of the company’s IMVAMUNE smallpox vaccine. With this order, the U.S. Government will continue to maintain the stockpile of IMVAMUNE for use in case of a public health emergency.
Since 2010, Bavarian Nordic has been delivering IMVAMUNE to the U.S. Strategic National Stockpile under a contract (RFP-3) for 20 million doses of the vaccine. The vaccine regards the use following a declared emergency in individuals of all ages with HIV infection or atopic dermatitis, including children, pregnant women, and nursing mothers, says Anders Hedegaard, President and CEO of Bavarian Nordic.
The first USD 110 million of the new order is secured, and the remaining portion will be secured based on availability of funds in 2014. Under the agreement, payments of additional USD 37 million will be received, associated with the delivery of the original 20 million dose order.